Cartesian Therapeutics
Clinical trials sponsored by Cartesian Therapeutics, explained in plain language.
A clinical-stage biotech developing RNA cell therapies for autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Engineered immune cells take on rare muscle disorders
Disease control Recruiting nowThis Phase 2 trial tests a personalized cell therapy called Descartes-08 for people with dermatomyositis or antisynthetase syndrome, two rare autoimmune diseases that cause muscle weakness and inflammation. The therapy uses a patient's own immune cells, modified to target and red…
Phase: PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Cell therapy Descartes-08 tested in teens with lupus and other autoimmune diseases
Disease control Recruiting nowThis early-stage trial is testing Descartes-08, a cell therapy made from modified immune cells, in 50 young people aged 12 and older with four autoimmune diseases: childhood-onset lupus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis. The stu…
Phase: PHASE1, PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Could a One-Time cell therapy ease myasthenia gravis? new trial launches
Disease control Recruiting nowThis phase 3 study tests an experimental treatment called Descartes-08 for adults with generalized myasthenia gravis, a condition causing muscle weakness. The therapy uses modified immune cells (mRNA CAR T-cells) to target the disease. About 100 participants will receive either t…
Phase: PHASE3 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC